Daisy C. Bridge
Research Subjects
Daisy C. Bridge has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte W. Oswald
Adelphi Values PROVE, Bollington, UK
2 shared publications - Christina Benninger
Johnson & Johnson, Titusville, USA
2 shared publications - Gurinderpal Doad
Johnson & Johnson, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA
2 shared publications - Luis Val Maranes
Adelphi Values PROVE, Bollington, UK
2 shared publications - Sheryl Wu
Pulmonary Vascular Medicine and Department of Pharmacy, University of California San Diego Health, La Jolla, USA
2 shared publications - Chad Miller
Piedmont Healthcare, Atlanta, USA
1 shared publication
Latest Publications
- Open Access
- 12 February 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (4) , 1384-1407
Transitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review
Introduction Oral selexipag is indicated to delay disease progression and reduce risk of pulmonary arterial hypertension (PAH)-related hospitalization, as demonstrated in GRIPHON. There are situations when clinicians or patients may need or want to transition from parenteral, oral, and inhaled prostacyclin pathway agents (PPAs) to oral selexipag. This systematic literature review (SLR) examined published evidence on such transitions in adults. Methods A SLR was conducted in Medline and Embase for publications from January 01, 2015 to September 25, 2024. Two reviewers independently screened abstracts and full texts; one extracted relevant data. Results Overall, 1730 publications were identified, with 48 included. Of these, 32 transitions from treprostinil and 16 from epoprostenol to oral selexipag were identified. Patient ages ranged from 19 to 78 years, with varying risk status and scores, functional classes, and comorbidities. Reasons for transition were patient-specific, with publications generally following GRIPHON and Food and Drug Administration (FDA) label protocols. Conclusion This review highlights cases where oral selexipag may be a suitable option when clinicians and patients participate in shared decision-making considering safety and risks/benefits. Transitions should be individualized based on clinical assessment, with appropriate monitoring and follow-up.
- 12 February 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (4) , 1384-1407
Open AccessTransitioning Prostacyclin Pathway Agents to Oral Selexipag in Patients with Pulmonary Arterial Hypertension: A Systematic Literature Review
Introduction Oral selexipag is indicated to delay disease progression and reduce risk of pulmonary arterial hypertension (PAH)-related hospitalization, as demonstrated in GRIPHON. There are situations when clinicians or patients may need or want to transition from parenteral, oral, and inhaled prostacyclin pathway agents (PPAs) to oral selexipag. This systematic literature review (SLR) examined published evidence on such transitions in adults. Methods A SLR was conducted in Medline and Embase for publications from January 01, 2015 to September 25, 2024. Two reviewers independently screened abstracts and full texts; one extracted relevant data. Results Overall, 1730 publications were identified, with 48 included. Of these, 32 transitions from treprostinil and 16 from epoprostenol to oral selexipag were identified. Patient ages ranged from 19 to 78 years, with varying risk status and scores, functional classes, and comorbidities. Reasons for transition were patient-specific, with publications generally following GRIPHON and Food and Drug Administration (FDA) label protocols. Conclusion This review highlights cases where oral selexipag may be a suitable option when clinicians and patients participate in shared decision-making considering safety and risks/benefits. Transitions should be individualized based on clinical assessment, with appropriate monitoring and follow-up.
- Open Access
- 9 January 2026
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 92, 102406
Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH)
- 9 January 2026
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 92, 102406
Open AccessSetting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH)